Genetically Modified T-Cells and PI3K/AKT Inhibitors For Cancer Treatment

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20230270855A1
SERIAL NO

17045802

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the field of cancer biology and immunology. More specifically, the present invention relates to the use of genetically modified immune cells in combination with certain chemotherapeutic agents for the treatment of cancer, wherein the genetically modified immune cells are resistant to said chemotherapeutic agents.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKP O BOX 6000 BINGHAMTON NY 13902-6000

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Lin, Richard East Setauket, US 45 654

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation